# | Title | Journal | Year | Citations |
---|
1 | ‘Acute myeloid leukemia: a comprehensive review and 2016 update’ | Blood Cancer Journal | 2016 | 885 |
2 | CAR-T cell therapy: current limitations and potential strategies | Blood Cancer Journal | 2021 | 871 |
3 | Acute lymphoblastic leukemia: a comprehensive review and 2017 update | Blood Cancer Journal | 2017 | 757 |
4 | The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion | Blood Cancer Journal | 2018 | 404 |
5 | Acute myeloid leukemia: current progress and future directions | Blood Cancer Journal | 2021 | 313 |
6 | Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia | Blood Cancer Journal | 2014 | 254 |
7 | Pathogenesis of bone disease in multiple myeloma: from bench to bedside | Blood Cancer Journal | 2018 | 219 |
8 | Acute promyelocytic leukemia: where did we start, where are we now, and the future | Blood Cancer Journal | 2015 | 211 |
9 | Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors | Blood Cancer Journal | 2015 | 190 |
10 | Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia | Blood Cancer Journal | 2015 | 188 |
11 | Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts | Blood Cancer Journal | 2016 | 181 |
12 | Multiple myeloma current treatment algorithms | Blood Cancer Journal | 2020 | 178 |
13 | Current status of autologous stem cell transplantation for multiple myeloma | Blood Cancer Journal | 2019 | 175 |
14 | Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria | Blood Cancer Journal | 2018 | 171 |
15 | Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study | Blood Cancer Journal | 2019 | 171 |
16 | Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting | Blood Cancer Journal | 2018 | 170 |
17 | Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 | Blood Cancer Journal | 2015 | 166 |
18 | High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites | Blood Cancer Journal | 2013 | 164 |
19 | Interpretation of cytogenetic results in multiple myeloma for clinical practice | Blood Cancer Journal | 2015 | 163 |
20 | Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions | Blood Cancer Journal | 2017 | 161 |
21 | Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing | Blood Cancer Journal | 2012 | 149 |
22 | Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update | Blood Cancer Journal | 2011 | 142 |
23 | Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients | Blood Cancer Journal | 2014 | 142 |
24 | CircRNAs in hematopoiesis and hematological malignancies | Blood Cancer Journal | 2016 | 139 |
25 | Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma | Blood Cancer Journal | 2020 | 137 |
26 | High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma | Blood Cancer Journal | 2017 | 132 |
27 | Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) | Blood Cancer Journal | 2020 | 131 |
28 | TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution | Blood Cancer Journal | 2015 | 130 |
29 | PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival | Blood Cancer Journal | 2015 | 129 |
30 | International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) | Blood Cancer Journal | 2020 | 126 |
31 | PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation | Blood Cancer Journal | 2015 | 124 |
32 | Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group | Blood Cancer Journal | 2017 | 124 |
33 | Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance | Blood Cancer Journal | 2013 | 118 |
34 | An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies | Blood Cancer Journal | 2015 | 117 |
35 | Myeloma cells suppress osteoblasts through sclerostin secretion | Blood Cancer Journal | 2011 | 113 |
36 | Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts | Blood Cancer Journal | 2018 | 113 |
37 | CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment | Blood Cancer Journal | 2017 | 108 |
38 | Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations | Blood Cancer Journal | 2012 | 107 |
39 | Myelodysplastic syndromes current treatment algorithm 2018 | Blood Cancer Journal | 2018 | 107 |
40 | The role of epigenetics in the biology of multiple myeloma | Blood Cancer Journal | 2014 | 106 |
41 | Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies | Blood Cancer Journal | 2021 | 106 |
42 | Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone | Blood Cancer Journal | 2019 | 104 |
43 | The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment | Blood Cancer Journal | 2021 | 103 |
44 | Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia | Blood Cancer Journal | 2016 | 102 |
45 | Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib | Blood Cancer Journal | 2015 | 101 |
46 | Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia | Blood Cancer Journal | 2016 | 101 |
47 | Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia | Blood Cancer Journal | 2020 | 101 |
48 | A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma | Blood Cancer Journal | 2015 | 100 |
49 | Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis | Blood Cancer Journal | 2015 | 100 |
50 | Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia | Blood Cancer Journal | 2021 | 100 |